.jpg)
METHOD FOR PROGNOSIS OF THE OUTCOME OF PATIENTS WITH HEART FAILURE (HF)
EP18706543; US16488067
The present invention offers a solution to the lack of a novel and efficient method capable to predict the outcome of patients with HF. In this context, patients with a bad prognosis are expected to be hospitalized or die in the incoming years following the diagnosis of HF, due to the HF, or due to a complication of the HF. This method is based on the concentration of Orosomucoid (APG) and Omentin in an isolated blood sample from the patient. In this sense, a high concentration of AGP and a low concentration of Omentin in blood are associated with a bad prognosis. This improved method of prognosis is aimed to help on the design of the most appropriate treatment for the patient.
HF Orome has a differential value with respect to the alternatives diagnosis and / or prognosis, where the European guidelines recommend the determination of type B natriuretic peptide (BNP) and N-terminal BNP (NT-proBNP) in plasma. However, its efficiency as a prognosis is low due to its modification by other factors such as age, renal failure or obesity. Therefore, one of its clear advantages lies in being a prognostic marker independent of age or associated risk factors. The HF_OROME kit represents a great advance with respect to the current tests since it could be used in POC and also identifies the patients with higher risk independently of age, heart rate, renal function and NTproBNP.